Eli Lil­ly and So­sei en­ter in­to di­a­betes and meta­bol­ic dis­ease deal, go­ing af­ter GPCR

3 years ago
Deals
R&D

BioN­Tech founder­s' on­col­o­gy start­up rolls up its sec­ond PhI­II win for Astel­las

3 years ago
R&D

Hem­genix now ap­proved, Paul Per­reault plans his ex­it from CSL; Lian­Bio pres­i­dent hands in res­ig­na­tion

3 years ago
Peer Review

De­bat­ing the p-val­ues be­hind Mod­er­na's $16B mar­ket-cap gain

3 years ago
R&D

De­spite 'lack­lus­ter' 2022, PwC re­mains 'bull­ish' on phar­ma M&A in 2023

3 years ago
Deals
Pharma

Ab­b­Vie opts out of in­dus­try trade groups PhRMA, BIO plus Busi­ness Round­table

3 years ago
Pharma

Up­dat­ed: FDA punts PDU­FA date for an­oth­er in­di­ca­tion for As­traZeneca, Mer­ck­'s can­cer drug Lyn­parza

3 years ago
Pharma
FDA+

Mer­ck marks 1M Minecraft down­loads in gam­ing-meets-sci­ence ed­u­ca­tion ef­fort

3 years ago
Pharma
Marketing

Fed­er­al Cir­cuit court halts delist­ing of Jazz nar­colep­sy drug patent from the Or­ange Book

3 years ago
Law

'Pro­ject Re­newal': FDA up­dates old­er Genen­tech can­cer drug la­bel

3 years ago
FDA+

What should man­u­fac­tur­ers do af­ter re­ceiv­ing a Form 483? FDA ex­plains

3 years ago
FDA+
Manufacturing

Af­ter a string of US projects, Ther­mo Fish­er opens the doors to a new fa­cil­i­ty in Chi­na

3 years ago
Manufacturing

Amid strep A out­break in the UK, gov­ern­ment watch­dog in­ves­ti­gates soar­ing an­tibi­ot­ic prices

3 years ago
R&D

Man­u­fac­tur­ing roundup: Phlow opens lab in Vir­ginia; Grand Riv­er Asep­tic Man­u­fac­tur­ing pur­chas­es more land close to ...

3 years ago
Manufacturing

No­vavax plans to raise $250M through stock, debt sales; Pen­ny stock com­pa­ny plans re­verse merg­er

3 years ago
News Briefing

Up­dat­ed: Maze re­veals pos­i­tive first look at PhI Pompe dis­ease can­di­date

3 years ago
R&D

Avid­i­ty clam­ors for $150M raise on heels of pos­i­tive da­ta read­out

3 years ago
Financing

Up­dat­ed: Tale of two ‘Abs’: Ab­b­Vie part­ners with an­ti­body biotech Ab­Cellera, but keeps de­tails un­der wraps

3 years ago
R&D

Scoop: Blade Ther­a­peu­tics CEO, CFO ap­pear to de­part amid 'tran­si­tion' af­ter nixed SPAC

3 years ago
Deals

Dis­con­tin­u­a­tion day: Third Har­mon­ic’s on­ly drug fails safe­ty study as BioCryst culls pipeline af­ter ASH

3 years ago
R&D

Ax­cel­la re­duces work­force by 85%, pri­or­i­tizes long Covid drug re­search

3 years ago
Coronavirus

En­laza launch­es with $61M, aims to take co­va­len­cy in­to pro­tein drugs

3 years ago
R&D

Sio fails to find buy­er, end­ing 'vant jour­ney in liq­ui­da­tion

3 years ago
R&D

Dan­ish biotech seek­ing niche vac­cine edge against Pfiz­er snags €72M for piv­otal study

3 years ago
Financing
First page Previous page 413414415416417418419 Next page Last page
A service from the Financial Times